Genix Pharmaceuticals Corporation

GENX

CA37232A1093

Food Processing

Delayed Toronto S.E. Other stock markets 13:44:16 2024-05-09 EDT			5-day change	1st Jan Change
0.05 ^CAD	+11.11%		+42.86%	+150.00%

03-26	Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
02-28	Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2023	CI

Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2020

March 28, 2021

Genix Pharmaceuticals Corporation announced earnings results for the full year ended October 31, 2020. For the full year, the company announced net loss was CAD 718,663 compared to CAD 164,701 a year ago. Basic loss per share from continuing operations was CAD 0.02.

Latest news about Genix Pharmaceuticals Corporation

Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2024	03-26	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2023	02-27	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-26	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-26	CI
Genix Pharmaceuticals Corporation Announces Board Changes	23-05-26	CI
Genix Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2022	23-02-27	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	22-09-14	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022	22-06-28	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2022	22-03-25	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2021	22-02-28	CI
Genix Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt	22-02-27	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter Ended July 31, 2021	21-09-21	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter Ended April 30, 2021	21-06-24	CI
Genix Pharmaceuticals : Starts Trading on OTCQB Venture Market Exchange	21-06-21	MT
Genix Pharmaceuticals Corporation Appoints Mahmoud Aziz to the Board and as President	21-05-20	CI
Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for First Generic Thyroid Medication	21-04-01	CI
Genix Pharmaceuticals Corporation Prepares to File Abbreviated New Drug Submissions for its First Ten Ophthalmic Drugs with Health Canada	21-03-22	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2020	21-02-28	CI
Genix Pharmaceuticals Corporation Announces Executive Changes	20-12-15	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter Ended July 31, 2020	20-09-28	CI
Genix Pharmaceuticals Corporation completed the acquisition of global distribution, sales and marketing rights and interest for Flu-X(r) from Canagen Pharmaceuticals Inc.	20-09-27	CI
Genix Pharmaceuticals Corporation Elects Darryl Yea to the Board of Directors	20-09-22	CI
Genix Pharmaceuticals Corporation Welcomes Monita Faris as Secretary	20-08-06	CI
Genix Pharmaceuticals Corporation announced that it has received CAD 1.026734 million in funding	20-08-05	CI

Chart Genix Pharmaceuticals Corporation

Duration

Period

More charts

Company Profile

Genix Pharmaceuticals Corporation is a nutraceutical and generic ophthalmic drugs company. The Company is focused on the research, development, manufacturing, licensing, and sales of healthcare products. Its products include evidence-based, proprietary over the counter (OTC) nutraceuticals, and other single-molecule generic drugs. The Company is engaged in marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Bimatoprost 0.01% Eye Drops, Timolol 0.5% Eye Drops, Loteprednol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Brimonidine 0.2% Eye Drops. The Company sells its ophthalmic products through traditional pharmacy and drugstore retail outlets and as well as direct to consumers and e-commerce platforms.

Sector

Food Processing

Calendar

2024-09-25 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
GENIX PHARMACEUTICALS CORPORATION	+150.00%	2.17M
ZHEJIANG NHU COMPANY LTD.	+19.40%	8.71B
BELLRING BRANDS, INC.	+8.05%	7.81B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+7.42%	6.69B
THE SIMPLY GOOD FOODS COMPANY	-6.24%	3.78B
BYHEALTH CO., LTD	-6.64%	3.77B
XIAMEN KINGDOMWAY GROUP COMPANY	-3.06%	1.41B
HERBALIFE LTD.	-27.23%	1.13B
SIRIO PHARMA CO., LTD.	+20.86%	1.07B
USANA HEALTH SCIENCES, INC.	-11.38%	906M

Special Foods & Wellbeing Products